Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
Opiranserin
Другие языки:

    Opiranserin

    Подписчиков: 0, рейтинг: 0
    Opiranserin
    Opiranserin.svg
    Clinical data
    Other names VVZ-149; VVZ-000149
    Routes of
    administration    		 Intravenous
    Identifiers
    • 4-Butoxy-N-([4-(dimethylamino)oxan-4-yl]methyl)-3,5-dimethoxybenzamide
    CAS Number
    PubChem CID
    UNII
    Chemical and physical data
    Formula C21H34N2O5
    Molar mass 394.512 g·mol−1
    3D model (JSmol)
    • O=C(NCC1(N(C)C)CCOCC1)C2=CC(OC)=C(OCCCC)C(OC)=C2
    • InChI=1S/C21H34N2O5/c1-6-7-10-28-19-17(25-4)13-16(14-18(19)26-5)20(24)22-15-21(23(2)3)8-11-27-12-9-21/h13-14H,6-12,15H2,1-5H3,(H,22,24)
    • Key:JQUVQWMHZSYCRQ-UHFFFAOYSA-N

    Opiranserin (INN; developmental code name VVZ-149) is a selective and combined glycine GlyT2 transporter blocker (IC50 = 0.86 μM), purine P2X3 receptor antagonist (IC50 = 0.87 μM), and serotonin 5-HT2A receptor antagonist (IC50 = 1.3 μM) which is under development by Vivozon for the intravenous treatment of postoperative pain. As of April 2017, it is in phase II clinical trials for this indication. The INN of the drug was issued in 2017.



    Новое сообщение